Utilization, cost, and specialty distribution of topical ruxolitinib prescribing in Medicare Part D, 2018-2024: A cross-sectional study.
Kent JA, Malave GS, Sacknovitz Y, Geskin LJ
JAAD InternationalIn the feed 19 Sep 2026, published online 23 Aug 2026, issue 2026 Oct, added to PubMed 19 Sep 2026
Topics: Atopic dermatitis & eczemaPigmentary disorders
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42761726 · DOI 10.1016/j.jdin.2026.08.003